

Aegerion Pharmaceuticals 2019 Methodology Document - ABPI Disclosure Reporting

Tax/VAT considerations:	Yearly amounts for each reportable HCP/HCO excluded VAT
Currency Aspects (including conversion rates):	All reported amounts are in British pounds. If the payment was made in another currency, the Company used the amount converted in British Pounds on the date of the invoice.
Cross Border Payments:	The Company searched for identified payments made to UK HCPs/HCOs from the US-based parent company (Aegerion, Inc.) or any of the Company's subsidiaries including Aegerion's UK- based subsidiary (Aegerion Ltd).
Multi-year contracts:	The Company reported all payments made to the reported HCPs/HCOs in calendar year 2019. If a contract contemplated payments to be made in subsequent calendar years, those payments will be reflected in those subsequent calendar years' filings.
Over-the-counter transfers of value:	N/A
Consent:	The contracts for the reported HCPs/HCOs included consent language between the Company and the reported HCP/HCO. The Company did require consent to be obtained in a stand-alone document.
Additional notes:	During the course of preparing our disclosure report, we became aware of a meal from January 2019 between our UK distributor and sub-contracted nurses. We do not have any additional details or supporting documentation for the meal/payment due to employee turnover, therefore, we were not able to determine if there were any potentially reportable transfers of value. However, we have addressed the gap in our data collection processes and are working to confirm that we do not miss any potentially reportable data in future reporting periods.

Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020

As part of the pharmaceutical industry's annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies' disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.)

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, Aegerion's 2019 transfer of value data has been published on Disclosure UK in aggregate.

Commitment to transparency

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

Link to company website for published disaggregated 2019 disclosure data

<https://www.amrytpharma.com/amryt-compliance/>